Sign in
TerminatedNo phase

MPS II Immunophenotyping

Key facts

Who runs it
Duke University
Where
Durham, United StatesSee the site
Trial code
Status
Terminated
People taking part
6 people enrolled
Started
1 Apr 2022
Ended
26 Apr 2024
Type of study
Observational, 3 groups
Record updated
19 September 2024
Why it stopped
Low Enrollment

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Subject has a confirmed diagnosis of Mucopolysaccharidosis type II (MPS II) or Hunter Syndrome based on enzyme activity and variant analysis
  • Subject who plan to receive or have received enzyme replacement therapy with idursulfase

Who cannot take part

  • None

Where in United States

  • Duke UniversityDurham, United States

About the trial

What the trial wants to find out

The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses to the ERT so that the investigators can relate the level of immune response to the treatment.

The 3 groups in the trial

  • Treatment Naive

    Subjects who are naïve to ERT and start treatment with idursulfase

  • Treatment less than 3 years

    Subjects who have received ERT for \<3 years

  • Treatment over 3 years

    Subjects who have received ERT for 3 or more years

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunophenotyping of Patients With MPS II Treated With Enzyme Replacement Therapy
Record updated
19 September 2024